Discover open access scientific publications

Search, annotate, share and cite publications

Publications by V. Ribrag

Single Nucleotide Polymorphisms in ABCB1 and CBR1 Can Predict Toxicity to R-Chop Type Regimens in Patients With Diffuse Non-Hodgkin Lymphoma

Haematologica
Hematology
2015English

Prophylactic Scrotal and Contralateral Testicular Radiation Therapy Prevents Local Relapses in Primary Testicular Lymphomas

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, a CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Molecular Landscape of Relapse/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy